yingweiwo

PRT062607 (P505-15, BIIB057) HCl

Alias: P505-15; P-50515; PRT2607; PRT062607; P50515; BIIB057; PRT-062607; PRT 062607; PRT-2607; PRT 2607; 1370261-96-3; PRT-062607; 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide; K9C42672RH; P505-15; BIIB057; UNII-K9C42672RH; P-505-15; P 505-15; P 50515; BIIB-057; BIIB 057.
Cat No.:V0652 Purity: ≥98%
PRT062607 (also known as P505-15, BIIB-057) HCl is a novel, potent, highly selective and orally bioavailablesmall molecule Syk inhibitor with potential anti-inflammatory activity.
PRT062607 (P505-15, BIIB057) HCl
PRT062607 (P505-15, BIIB057) HCl Chemical Structure CAS No.: 1370261-97-4
Product category: Syk
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes

Other Forms of PRT062607 (P505-15, BIIB057) HCl:

  • PRT062607
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

PRT062607 (also known as P505-15, BIIB-057) HCl is a novel, potent, highly selective and orally bioavailable small molecule Syk inhibitor with potential anti-inflammatory activity. It inhibits Syk with an IC50 of 1 nM in cell-free assays, and shows >80-fold selectivity for Syk over other kinases such as Fgr, Lyn, FAK, Pyk2 and Zap70. PRT062607 produced excellent in vivo anti-inflammatory activity in two rodent models of rheumatoid arthritis. P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL. PRT062607effectively antagonize CLL cell survival after BCR triggering. Moreover, they inhibit the secretion of the chemokines CCL3 and CCL4 by CLL cells, and leukemia cell transfer toward beneath stromal cells, the tissue homing chemokines CXCL13 and CXCL12.

Biological Activity I Assay Protocols (From Reference)
Targets
Lck (IC50 = 249 nM); PAK5 (IC50 = 166 nM)
ln Vitro
PRT062607 (P505-15) is a brand-new, extremely effective, and strong small-molecule inhibitor of Syk that is taken orally. Two distinct pure kinase assays are used to investigate PRT062607's efficacy against its target kinase Syk. Half-maximum Syk inhibition needed 6±0.2 nM (mean±SEM) according to a FRET test. A radioactive enzyme assay yields a Syk IC50 of 2.1±0.4 nM (mean±SEM), indicating similar potency. PRT062607 effectively suppresses Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM) and B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) in human whole blood[1].
ln Vivo
When PRT062607 (P505-15) is administered orally to mice in the CAIA model, the average reduction in paw inflammation, as determined by daily scoring of inflammation in comparison to vehicle controls, is 12, 44, and 87%. At the conclusion of the study, the average plasma concentration (C average over 24 hours) was determined to be 0.38, 0.95, and 1.47 μM. Mice given 30 mg/kg of PRT062607 showed a considerable reduction in joint degeneration, to the point that the mice could not be distinguished from normal mice. By the end of the research, the majority of the animals (seven out of eight) in the rat CIA model (mean inflammation score±SEM=0.63±1.1; p<0.0001 versus vehicle) had totally suppressed inflammation due to the high dose of PRT062607 (15 mg/kg bid)[1].
In human whole blood, P505-15 potently inhibited B cell antigen receptor-mediated B cell signaling and activation (IC50 0.27 and 0.28 μM, respectively) and Fcε receptor 1-mediated basophil degranulation (IC50 0.15 μM). Similar levels of ex vivo inhibition were measured after dosing in mice (Syk signaling IC50 0.32 μM). Syk-independent signaling and activation were unaffected at much higher concentrations, demonstrating the specificity of kinase inhibition in cellular systems. Oral administration of P505-15 produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis. Statistically significant efficacy was observed at concentrations that specifically suppressed Syk activity by ∼67%. Thus specific Syk inhibition can mimic Syk genetic deficiency to modulate immune function, providing a therapeutic strategy in P505-15 for the treatment of human diseases.[2]
Enzyme Assay
SYK Autophosphorylation. [1]
Ramos cells (107 cells per experiment) were preincubated for 30 minutes with or without PRT062607 (P505-15)  and then stimulated (30 minutes at 37°C) with 1 μg/ml anti-IgM. Signaling was terminated by resuspending cells in RIPA lysis buffer (50 mM Tris 7.4, 1% NP40, 0.5% sodium deoxycholate, 150 mM NaCl, 0.5 mM EDTA) containing fresh protease and phosphatase inhibitors and incubated on ice for 1 hour. Following centrifugation, protein lysates were pre-cleared with protein A/G sepharose beads. Lysates were incubated overnight (4°C) with rabbit anti-SYK antibody and precipitated with protein A/G sepharose beads. Washed beads were denatured and proteins were resolved by 10% SDS-PAGE, immunoblotted with rabbit anti-SYK antibody, stripped, and reblotted with rabbit anti-pSYK Y526/526 antibody.
Cell Assay
Intracellular Phospho-flow Cytometry. [1]
Ramos cells (0.5 × 106) were suspended in 200 μl fresh media (RPMI plus 10% fetal calf serum) and pretreated with vehicle or PRT062607 (P505-15)  (30 minutes at 37°C). Cells were left unstimulated or were stimulated with 1 μg/ml goat F(ab)’2 anti-IgM (Life Technologies) for 10 minutes. Ficoll purified (2 × 106) frozen viable CLL cells obtained from peripheral blood of CLL patients (n = 7) were thawed at 37°C, washed in 10 ml RPMI media plus 10% fetal calf serum by centrifugation, and resuspended at 106 cells/ml in the same media. Aliquots (200 μl) of cells were treated with vehicle or PRT062607 (P505-15)  for 30 minutes prior to stimulation with 0.3 mM H2O2 (Reth 2002; Irish et al., 2006) (8.8 M stock) followed by addition of 6 μg of a 1:1 mixture of goat F(ab’)2 anti-human IgG and anti-human IgM for 10 minutes. Signaling was stopped by addition of 60 μl of a 16% paraformaldehyde solution followed by 10-minute incubation at room temperature. Fixed cells were washed twice in ice-cold phosphate buffered saline (PBS) by centrifugation, suspended in a 50% methanol solution in PBS prechilled to −20°C, and stored at 4°C overnight. Cells were stained for intracellular phosphoflow cytometry by washing the permeabilized cells twice in PBS containing 1% BSA, followed by incubation in the same buffer containing various antibodies, as indicated in the results, per manufacturer instructions. Cells were washed once more in PBS containing 1% BSA prior to FACS analysis, in which at least 2,000 events were collected using a BD Biosciences FACS Calibur. Data were analyzed using FlowJo software.
Apoptosis. [1]
Apoptosis was measured using the PE-conjugated monoclonal active caspase-3 antibody apoptosis kit. Cells were suspended in growth media (0.5 × 106 cells/ml) and treated with the indicated concentrations of PRT062607 (P505-15)  or vehicle control for 72 hours prior to FACS analysis. In some experiments, SU-DHL6 (0.5 × 106 cells) was mixed with 100 µl heparinized human whole blood. Samples were treated with 1 µM PRT062607 (P505-15)  for 24 hours and then surface stained with anti-human CD19 antibody prior to preparation for FACS analysis of active caspase-3.
Animal Protocol
In Vitro and In Vivo Stimulation with Anti-IgD. [1]
Spleens were harvested from Balb/c mice and separated into a single cell suspension using a single cell strainer. Cells were collected in PBS containing 1% BSA by centrifugation, washed once in the same buffer, and resuspended in RPMI (containing 10% FCS) at 106 cells/ml. Aliquots (190 µl) were then treated with various concentrations of PRT062607 (P505-15)  for 1 hour prior to stimulating overnight in a 37°C tissue culture incubator with 1 µl anti-mouse immunoglobulin D (IgD). Following stimulation, cells were stained with anti-CD80/86 FITC and anti-CD45R/B220 APC for 30 minutes at room temperature, washed once in PBS containing 1% BSA, and resuspend in 300 μl of the same buffer for collection of 2000 CD45-positive events by flow cytometry. Balb/c mice (n = 5 per group) received daily oral BID doses of vehicle (0.5% methylcellulose in water) or PRT062607 (P505-15)  (15 mg/kg) for a total of 5 days. On study day 1, 1 hour after the first oral dose, mice received a single 200-μl subcutaneous injection of control goat serum or anti-IgD serum. On study day 5, mice were anesthetized with SC ketamine cocktail and exsanguinated via cardiac puncture. Spleens were weighed and then sectioned and stained with hematoxylin and eosin for histology.
Xenograft Studies. [1]
NOD/SCID mice were acclimated in-house at least 3 days prior to use. Ramos cells (3 × 106) were injected subcutaneously into the hind flank area of conscious mice using a 27-gauge needle in an injection volume of less than 0.5 ml. Following injection, mice were randomized into treatment groups (n = 15) and dosed twice daily by oral gavage with vehicle (0.5% methylcellulose in water) or 10, 15, or 20 mg/kg PRT062607 (P505-15) . Body weights were obtained at least once per week, and caliper measurements of tumors were determined twice per week beginning when palpable tumors were formed until the end of the study. Tumor volume was assessed by caliper measurement using a formula [maximum length × width × height × pi/6]. Twice daily dosing of vehicle or PRT062607 (P505-15)  continued until the vehicle or any treatment group exhibited tumors that exceeded 1.5 g in size. At the time of termination (5 weeks post-Ramos inoculation) the mice were anesthetized with a ketamine cocktail. A blood sample via cardiac puncture was obtained for CBC and plasma concentration determination, and then the mice were euthanized via cervical dislocation. Tumors were excised, weighed, and then snap frozen in liquid nitrogen for determination of concentration of PRT062607 (P505-15)  in the tumor tissue. Statistical comparison of tumor weights across groups was performed using a t-test.
10, 15, or 20 mg/kg; Oral administration
NOD/SCID mice injected with Ramos cells
References

[1]. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87.

[2]. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9.

Additional Infomation
Given its preclinical activity and specificity, especially when compared with previously studied SYK inhibitors, P505-15 is an attractive compound for clinical development. Additional studies aimed at defining the biologic characteristics associated with SYK sensitivity are needed. Exploring additional P505-15 combinations including chemotherapy, monoclonal antibodies, or novel combinations of kinase inhibitors targeting multiple branches of signaling pathways, may identify further therapeutic opportunities. A dose finding study using P505-15 in healthy volunteers has been completed and includes single and multiple dosing regimens.[1]
B-cell receptor (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies. SYK is persistently phosphorylated in a subset of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), and SYK inhibition results in abrogation of downstream kinase activity and apoptosis. P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases. We evaluated the preclinical characteristics of P505-15 in models of NHL and CLL. P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL. Oral dosing in mice prevented BCR-mediated splenomegaly and significantly inhibited NHL tumor growth in a xenograft model. In addition, combination treatment of primary CLL cells with P505-15 plus fludarabine produced synergistic enhancement of activity at nanomolar concentrations. Our findings support the ongoing development of P505-15 as a therapeutic agent for B-cell malignancies. A dose finding study in healthy volunteers has been completed.[2]
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C19H23N9O.HCL
Molecular Weight
429.91
Exact Mass
429.179
Elemental Analysis
C, 53.08; H, 5.63; Cl, 8.25; N, 29.32; O, 3.72
CAS #
1370261-97-4
Related CAS #
PRT062607;1370261-96-3
PubChem CID
56948527
Appearance
Light yellow to khaki solid powder
LogP
3.463
Hydrogen Bond Donor Count
5
Hydrogen Bond Acceptor Count
8
Rotatable Bond Count
6
Heavy Atom Count
30
Complexity
544
Defined Atom Stereocenter Count
2
SMILES
C1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N.Cl
InChi Key
RMNLLPXCNDZJMJ-IDVLALEDSA-N
InChi Code
InChI=1S/C19H23N9O.ClH/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28;/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27);1H/t15-,16+;/m0./s1
Chemical Name
4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride
Synonyms
P505-15; P-50515; PRT2607; PRT062607; P50515; BIIB057; PRT-062607; PRT 062607; PRT-2607; PRT 2607; 1370261-96-3; PRT-062607; 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide; K9C42672RH; P505-15; BIIB057; UNII-K9C42672RH; P-505-15; P 505-15; P 50515; BIIB-057; BIIB 057.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 86 mg/mL (200.0 mM)
Water:<1 mg/mL
Ethanol:86 mg/mL (200.0 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: Saline:30mg/mL

Solubility in Formulation 5: 50 mg/mL (116.30 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.3261 mL 11.6303 mL 23.2607 mL
5 mM 0.4652 mL 2.3261 mL 4.6521 mL
10 mM 0.2326 mL 1.1630 mL 2.3261 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01652937 Withdrawn Drug: BIIB057
Drug: Placebo
Rheumatoid Arthritis Biogen August 2012 Phase 2
Biological Data
  • PRT062607 (P505-15, BIIB057) HCl

    P505-15 selectively inhibits proliferation of Syk-dependent B cell lines.J Pharmacol Exp Ther.2012 Feb;340(2):350-9.

  • PRT062607 (P505-15, BIIB057) HCl

    P505-15 attenuates antibody-induced inflammation in a mouse model of rheumatoid arthritis.J Pharmacol Exp Ther.2012 Feb;340(2):350-9.

  • PRT062607 (P505-15, BIIB057) HCl

    Oral administration of P505-15 significantly ameliorates the severity and development of arthritis in the rat CIA model.J Pharmacol Exp Ther.2012 Feb;340(2):350-9.

Contact Us